Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting on December 7, 2025 · Leave a Comment DALY 2–EU results show zamtocabtagene autoleucel (zamto–cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B–cell lymphoma [...] Read more »